This is one of the highest-stakes topics in men's hormone care. Marketing that frames injections as "just optimizing" without fertility counseling fails basic informed consent. Likewise, calling compounded enclomiphene a guaranteed fertility-safe TRT substitute overstates the regulatory and evidence reality. See also: what your testosterone labs actually mean.
What it is
Testosterone injections (and other exogenous T): FDA-approved testosterone products replace or supplement testosterone for labeled hypogonadism indications. They raise circulating T but provide negative feedback to the hypothalamic–pituitary–gonadal (HPG) axis, lowering LH/FSH and typically reducing intratesticular testosterone needed for normal sperm production.
Enclomiphene citrate: The trans-isomer of clomiphene. Investigational programs (historically Androxal®/Enclomiphene from Repros) studied oral enclomiphene in overweight men with secondary hypogonadism. Mechanism (simplified): estrogen receptor blockade at the hypothalamus/pituitary can increase LH/FSH, stimulating endogenous testicular testosterone production—unlike exogenous T, which replaces the signal.
Clomiphene citrate (a mixture of enclomiphene and zuclomiphene) is sometimes used off-label in men; that practice is clinician-dependent and distinct from an FDA-approved male hypogonadism indication for enclomiphene (which does not exist).
How it works
| Approach | Axis effect (typical) | Fertility implications (typical) |
|---|---|---|
| Exogenous testosterone injections/gels/pellets | Suppresses LH/FSH | Sperm counts often fall; may cause azoospermia; recovery variable after stopping |
| Enclomiphene (investigational / compounded use) | Can raise LH/FSH and endogenous T in secondary hypogonadism studies | Phase 3 programs reported better maintenance of sperm concentration vs testosterone gel in studied populations—still not FDA-approved |
Endocrine Society guidance recommends against testosterone therapy in men planning fertility in the near term.
What evidence shows
| Topic | Status |
|---|---|
| Exogenous T suppresses spermatogenesis | Established — reflected in guidelines counseling against T when near-term fertility is desired |
| Enclomiphene raised T and maintained sperm parameters better than T gel in Repros phase 3 programs | Emerging / published trial data (e.g., Journal of Urology abstract; NCT01739595); not the same as FDA approval |
| FDA approval of enclomiphene for male hypogonadism | Not approved — Complete Response Letter (Dec 2015) cited study design/adequacy concerns |
| Compounded enclomiphene equals an approved drug | Unproven — compounded drugs are not FDA-approved |
| Guaranteed preservation of fertility on any SERM protocol | Unproven — individual responses vary; semen analysis still required for fertility planning |
FDA review materials summarizing enclomiphene programs have also noted that normalizing testosterone alone may not establish clinically meaningful benefit by the Agency's standards, and that semen-parameter changes alone are not sufficient to prove fertility improvement.
Risks
Exogenous testosterone: erythrocytosis, acne, edema, infertility/subfertility while on therapy, potential sleep apnea worsening, blood-pressure increases, need for monitoring; contraindications/precautions per label and guidelines.
Enclomiphene / SERM class considerations: visual symptoms have been discussed with clomiphene historically; mood changes; estrogen-pathway effects; off-label and compounded use may lack the manufacturing and evidence standards of approved products. Lack of FDA approval means benefit–risk is less clearly defined for routine care.
Shared risk: Treating labs without addressing obesity, sleep apnea, or depression.
Who should discuss with a clinician
- Men with hypogonadal symptoms who want children now or within a few years
- Men already on TRT who were not counseled about sperm banking or alternatives
- Couples in fertility care who need coordinated endocrinology/urology input
- Anyone offered "fertility-safe TRT" online without semen testing or a clear regulatory explanation
Sperm cryopreservation before exogenous T is a concrete option many men never hear early enough.
Bottom Line
If near-term fertility matters, exogenous testosterone is generally the wrong first move—guidelines say so. Enclomiphene has intriguing trial data for raising T while sparing sperm counts relative to testosterone gel in specific secondary hypogonadism populations, but it remains unapproved, and compounded versions are not FDA-approved substitutes. Fertility planning needs semen analysis and specialist input, not slogans.
So what?
Before starting injections, ask explicitly: "How will this affect my sperm count, and what are evidence-based alternatives if I want children?" Get answers in writing in your care plan.
Scoreboard Health can help you understand evaluation pathways with licensed clinicians—including fertility-sensitive conversations—via How it works or Treatments.
Related reading
Disclaimer: Educational content only. Not medical advice. Enclomiphene is not FDA-approved. Compounded medications are not FDA-approved. Fertility decisions require appropriate specialists.
Medically reviewed by: Ariel Bowerman, BSN, R.N.
Sources
- Bhasin S, et al. Endocrine Society testosterone guideline (2018)—recommends against T therapy when planning near-term fertility. PubMed
- ClinicalTrials.gov. NCT01739595 — Phase III enclomiphene (Androxal) morning testosterone study. clinicaltrials.gov
- AUA Journals abstract: Endroxal (enclomiphene) vs AndroGel spermatogenesis findings. auajournals.org
- Repros Therapeutics — FDA Complete Response Letter announcement (SEC), Dec 1, 2015. sec.gov
- FDA. Andrology-related review materials discussing enclomiphene programs. fda.gov
- MedlinePlus. Testosterone Levels Test. medlineplus.gov
Learn how Scoreboard Health structures men's evaluation pathways: How it works · Treatments